Return to insights

Analysis of the economic benefits of oncology clinical research in Quebec

Since the aging population accentuates the impact of cancer in Quebec, the Quebec–Clinical Research Organization in Cancer (Q–CROC) commissioned Aviseo Consulting to assess the economic impact of oncology research in Quebec. Q–CROC is a network of researchers, professionals, and institutions that serves as a catalyst for research by facilitating patient recruitment, the sharing of best practices, and compliance with current standards. The main goal of oncology research is to improve patients’ quality of life and survival rates. Not only does the research support over 900 jobs, but it also allows patients to live active lives for longer, reduces costs for the health care system, and generates tax benefits for governments.

Q-CROC - Analyse des bénéfices économiques de la recherche clinique en oncologie au Québec

Key figures

Cancer cost an estimated $3.3 billion in 2017.
In Canada, 30% of deaths are related to the progression of a cancerous tumour, with 80% of these deaths occurring when individuals are aged 60 plus.
Oncology research in Quebec represents between $188 million and $230 million annually.
There are currently 1,400 studies that are either in the early stages, in the recruitment phase, or ongoing.
Of the oncology clinical studies in the Q-CROC network, 60% are funded by the pharmaceutical industry.
There has been a 12% increase per year in the number of participants in oncology studies.
Currently, 46% of studies are meeting their recruitment targets, as compared to 41% in 2014.
According to a literature review, oncology research increases 10-year survival rates by 10% and this increase occurs 10 years after studies are conducted. This is equivalent to an additional 3,400 survivors per year.
The economic impact of oncology research in Quebec is $112 million, $28 million of which comes from increased patient survival.